Abstract
Glioblastoma (GBM) is a grade-IV astrocytoma, which is the most common and aggressive type of brain tumor, spreads rapidly and has a life-threatening catastrophic effect. GBM mostly occurs in adults with an average survival time of 15 to 18 months, and the overall mortality rate is 5%. Significant invasion and drug resistance activity cause the poor diagnosis of GBM. Naringenin (NRG) is a plant secondary metabolite byproduct of the flavanone subgroup. NRG can cross the blood-brain barrier and deliver drugs into the central nervous system when conjugated with appropriate nanocarriers to overcome the challenges associated with gliomas through naringenin-loaded nanoformulations. Here, we discuss several nanocarriers employed that are as delivery systems, such as polymeric nanoparticles, micelles, liposomes, solid lipid nanoparticles (SLNs), nanosuspensions, and nanoemulsions. These naringenin-loaded nanoformulations have been tested in various in vitro and in vivo models as a potential treatment for brain disorders. This review nanoformulations of NRG can a possible therapeutic alternative for the treatment of neurological diseases are discussed.
Keywords: Glioblastoma, nanoparticles, naringenin, nanoformulations, flavonoid, neurodegenerative diseases.
Current Pharmaceutical Biotechnology
Title:Naringenin Nanoformulations for Neurodegenerative Diseases
Volume: 25 Issue: 16
Author(s): Liza Sahoo, Nigam Sekhar Tripathy and Fahima Dilnawaz*
Affiliation:
- Department of Biotechnology, School of Engineering and Technology, Centurion University of Technology and Management, Jatni, 752050, Bhubaneswar, Odisha, India
Keywords: Glioblastoma, nanoparticles, naringenin, nanoformulations, flavonoid, neurodegenerative diseases.
Abstract: Glioblastoma (GBM) is a grade-IV astrocytoma, which is the most common and aggressive type of brain tumor, spreads rapidly and has a life-threatening catastrophic effect. GBM mostly occurs in adults with an average survival time of 15 to 18 months, and the overall mortality rate is 5%. Significant invasion and drug resistance activity cause the poor diagnosis of GBM. Naringenin (NRG) is a plant secondary metabolite byproduct of the flavanone subgroup. NRG can cross the blood-brain barrier and deliver drugs into the central nervous system when conjugated with appropriate nanocarriers to overcome the challenges associated with gliomas through naringenin-loaded nanoformulations. Here, we discuss several nanocarriers employed that are as delivery systems, such as polymeric nanoparticles, micelles, liposomes, solid lipid nanoparticles (SLNs), nanosuspensions, and nanoemulsions. These naringenin-loaded nanoformulations have been tested in various in vitro and in vivo models as a potential treatment for brain disorders. This review nanoformulations of NRG can a possible therapeutic alternative for the treatment of neurological diseases are discussed.
Export Options
About this article
Cite this article as:
Sahoo Liza, Tripathy Sekhar Nigam and Dilnawaz Fahima*, Naringenin Nanoformulations for Neurodegenerative Diseases, Current Pharmaceutical Biotechnology 2024; 25 (16) . https://dx.doi.org/10.2174/0113892010281459240118091137
DOI https://dx.doi.org/10.2174/0113892010281459240118091137 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IgG Dimers in Multidonor-Derived Immunoglobulins: Aspects of Generation and Function
Current Pharmaceutical Design Acute to Subacute Spinal Cord Infarction Mimicking Acute Multiple Sclerosis: Usefulness of Diffusion-weighted MRI for Diagnosis
Current Medical Imaging Exploring the Therapeutic Potential of Phytoconstituents for Addressing Neurodegenerative Disorders
Central Nervous System Agents in Medicinal Chemistry Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets <i>In silico</i> Evaluation and Neuroprotective Effect of Jasmonic Acid on Sleep Deprivation Induced Alzheimer’s in Zebrafish
Current Bioactive Compounds Articulating A Rights-Based Approach to HIV Treatment and Prevention Interventions
Current HIV Research Molecular Interaction of Acetylcholinesterase with Carnosic Acid Derivatives: A Neuroinformatics Study
CNS & Neurological Disorders - Drug Targets Zinc as an Appetite Stimulator - The Possible Role of Zinc in the Progression of Diseases Such as Cachexia and Sarcopenia
Recent Patents on Food, Nutrition & Agriculture Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Current Pharmaceutical Design Lipid Oxidation Products in the Pathogenesis of Inflammation-related Gut Diseases
Current Medicinal Chemistry Potential of Nanotechnology-based Formulations in Combating Pulmonary Infectious Diseases: A Current Scenario
Current Pharmaceutical Design In Vitro and Ex Vivo Model Systems to Measure ABC Transporter Activity at the Blood-Brain Barrier
Current Pharmaceutical Design Neurovascular Mechanisms of Hypertension in Pregnancy
Current Neurovascular Research Extended Application of Digital Clock Drawing Test in the Evaluation of Alzheimer’s Disease Based on Artificial Intelligence and the Neural Basis
Current Alzheimer Research High-throughput Sequencing and Bioinformatics Analysis Reveals the Neurogenesis Key Targets of Curcumin Action in Mouse Brain with MCAO
Combinatorial Chemistry & High Throughput Screening Ameliorative Effect of Trans-Sinapic Acid and its Protective Role in Cerebral Hypoxia in Aluminium Chloride Induced Dementia of Alzheimer's Type
CNS & Neurological Disorders - Drug Targets Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design Systemic Administration of Fluoro-Gold for the Histological Assessment of Vascular Structure, Integrity and Damage
Current Neurovascular Research Neurodegeneration in Niemann-Pick Type C Disease and Huntingtons Disease: Impact of Defects in Membrane Trafficking
Current Drug Targets Metabolic Imaging through Continuous In Situ Micro-extractions of Tissue Samples via Flowprobe Mass Spectrometry
Current Metabolomics